J. Clark

A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients.

D. Bergstrom, G. Shapiro, J. Eder, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

A. Nagler, I. Dufva, G. Martinelli, 2014, Blood Cancer Journal.

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Yang Liu, S. Koletar, J. Lake, 2022, The Lancet Infectious Diseases.